Literature DB >> 32175433

Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes.

Xiaoxia Chen1, Chunxia Su1, Shengxiang Ren1, Caicun Zhou1, Tao Jiang1.   

Abstract

Entities:  

Year:  2020        PMID： 32175433      PMCID： PMC7048975          DOI： 10.21037/atm.2019.11.52

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  15 in total

1.  EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.

Authors:  Antonio Marzio; Emma Kurz; Jennifer M Sahni; Giuseppe Di Feo; Joseph Puccini; Shaowen Jiang; Carolina Alcantara Hirsch; Arnaldo A Arbini; Warren L Wu; Harvey I Pass; Dafna Bar-Sagi; Thales Papagiannakopoulos; Michele Pagano
Journal:  Cell       Date:  2021-12-27       Impact factor: 41.582

2.  KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials.

Authors:  Hongyuan Zhu; Daipeng Xie; Yunfang Yu; Lintong Yao; Bin Xu; Luyu Huang; Shaowei Wu; Fasheng Li; Yating Zheng; Xinyi Liu; Wenzhuan Xie; Mengli Huang; Hao Li; Shaopeng Zheng; Dongkun Zhang; Guibin Qiao; Lawrence W C Chan; Haiyu Zhou
Journal:  Front Oncol       Date:  2021-07-26       Impact factor: 6.244

Review 3.  The Taming of Nuclear Factor Erythroid-2-Related Factor-2 (Nrf2) Deglycation by Fructosamine-3-Kinase (FN3K)-Inhibitors-A Novel Strategy to Combat Cancers.

Authors:  Narasimha M Beeraka; Venugopal R Bovilla; Shalini H Doreswamy; Sujatha Puttalingaiah; Asha Srinivasan; SubbaRao V Madhunapantula
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

4.  Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.

Authors:  Wei Nie; Lu Gan; Xin Wang; Kai Gu; Fang-Fei Qian; Min-Juan Hu; Ding Zhang; Shi-Qing Chen; Jun Lu; Shu-Hui Cao; Jing-Wen Li; Yue Wang; Bo Zhang; Shu-Yuan Wang; Chang-Hui Li; Ping Yang; Mi-Die Xu; Xue-Yan Zhang; Hua Zhong; Bao-Hui Han
Journal:  Oncoimmunology       Date:  2021-01-15       Impact factor: 8.110

5.  [Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].

Authors:  Chang Jiang; Ling Yi; Xiang Gao; Hongtao Zhang; Shucai Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-01-20

Review 6.  The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

Authors:  Denis L Jardim; Aaron Goodman; Debora de Melo Gagliato; Razelle Kurzrock
Journal:  Cancer Cell       Date:  2020-10-29       Impact factor: 31.743

7.  The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration.

Authors:  Chenyue Zhang
Journal:  J Transl Med       Date:  2021-06-14       Impact factor: 5.531

8.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

Authors:  Ferdinandos Skoulidis; Bob T Li; Grace K Dy; Timothy J Price; Gerald S Falchook; Jürgen Wolf; Antoine Italiano; Martin Schuler; Hossein Borghaei; Fabrice Barlesi; Terufumi Kato; Alessandra Curioni-Fontecedro; Adrian Sacher; Alexander Spira; Suresh S Ramalingam; Toshiaki Takahashi; Benjamin Besse; Abraham Anderson; Agnes Ang; Qui Tran; Omar Mather; Haby Henary; Gataree Ngarmchamnanrith; Gregory Friberg; Vamsidhar Velcheti; Ramaswamy Govindan
Journal:  N Engl J Med       Date:  2021-06-04       Impact factor: 176.079

Review 9.  The cutting-edge progress of immune-checkpoint blockade in lung cancer.

Authors:  Fei Zhou; Meng Qiao; Caicun Zhou
Journal:  Cell Mol Immunol       Date:  2020-11-11       Impact factor: 22.096

10.  Keap1 inhibition sensitizes head and neck squamous cell carcinoma cells to ionizing radiation via impaired non-homologous end joining and induced autophagy.

Authors:  Sara Sofia Deville; Susanne Luft; Maria Kaufmann; Nils Cordes
Journal:  Cell Death Dis       Date:  2020-10-21       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.